SAB Biotherapeutics (SABS) Set to Release Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABS) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect SAB Biotherapeutics to announce earnings of ($0.27) per share and revenue of $0.12 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting the consensus estimate of ($0.28). On average, analysts expect SAB Biotherapeutics to post ($1.17) EPS for the current fiscal year and ($0.79) EPS for the next fiscal year.

SAB Biotherapeutics Stock Performance

Shares of SABS stock traded up $0.17 during mid-day trading on Wednesday, reaching $3.29. 73,005 shares of the company’s stock traded hands, compared to its average volume of 637,186. SAB Biotherapeutics has a 12 month low of $2.44 and a 12 month high of $5.15. The firm has a 50 day moving average price of $3.24 and a two-hundred day moving average price of $3.68. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.22 and a current ratio of 9.22. The firm has a market capitalization of $298.90 million, a PE ratio of -2.52 and a beta of 0.67.

Analysts Set New Price Targets

Several research firms recently weighed in on SABS. Weiss Ratings upgraded SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Wall Street Zen upgraded SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 10th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.